Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fresenius Medical Care AG & Co. KGAA

Division of Fresenius SE & Co. KGAA
www.fmc-ag.com

Latest From Unigene Laboratories Inc.

FDA Keeps Calcitonin Products On The Market But Narrows Osteoporosis Claim

Saying its review found “no conclusive evidence of a causal relationship” between the products and cancer, agency is allowing continued marketing of Miacalcin and Fortical nasal sprays but limiting use to only those post-menopausal women for whom alternative treatments are not suitable.

BioPharmaceutical United States

Deals of the Week: Is Astex Settling For An Underpriced Buyout?

A new life sciences hedge fund operated by two former associates of activist investor Carl Icahn is challenging Otsuka’s takeover of cancer drug developer Astex. Also, Johnson & Johnson’s London Innovation Center announced four alliances, Celgene took another option on one of its investments and Takeda teamed up with New York research institutions to form a new discovery institute.

BioPharmaceutical United States

Enteris Begins Its Phoenix Story With Nordic Deal

Newly formed Enteris inks its first licensing deal as it tries to prove to potential partners that its technology can help company up-cycle old drugs and improve their patent life by making them orally available.

BioPharmaceutical North America

Regenerating Interest In Novel Drugs For Postmenopausal Osteoporosis

New bone-targeted agents for osteoporosis must clear significant obstacles to succeed in a highly generic market, but safety concerns with established agents like bisphosphonates and calcitonin offer a foothold. Phase III anabolic candidates from Amgen and Radius Health aim to build new bone, the holy grail of osteoporosis treatment, but R&D in new anti-resorptive mechanisms to halt bone breakdown also continues.

BioPharmaceutical Clinical Trials
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register